Study Summary
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
Want to learn more about this trial?
Request More InfoInterventions
CAR-T/TCR-T cells immunotherapyBIOLOGICAL
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Henan Provincial People's Hospital | Zhengzhou | Henan | China |